PURPOSE: A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II study designed to confirm this result. PATIENTS AND METHODS: The concurrent phase consisted of two cycles of cisplatin, etoposide, and once-daily radiation to 61 Gy. TPZ was given at 260 mg/m(2) on days 1, 29, and at 160 mg/m(2) on days 8, 10, 12, 36, 38, and 40. Consolidation consisted of two cycles of cisplatin and etoposide. Complete responders received prophylactic cranial irradiation. Results were considered promising if the median survival time was at least 21 months and of no further interest if < or = 14 months. RESULTS: S0222 was closed early due to a report of excess toxicity for TPZ in a head and neck cancer trial elsewhere. Of planned 85 patients, 69 were accrued. In 68 assessable patients, 17 (25%) had grade 3 to 4 esophagitis and eight (12%) had grade 3 febrile neutropenia during the concurrent phase. There were three possible treatment-related deaths, two in concurrent phase (one progressive disease not otherwise specified within 30 days, one pericardial effusion) and one in consolidation phase (esophageal hemorrhage). At a median follow-up of 35 months, median progression-free survival was 11 months (95% CI, 10 to 13 months) and median overall survival was 21 months (95% CI, 17 to 33 months). CONCLUSION: S0222 showed acceptable levels of toxicity and similar promising median survival as S0004. Further study of hypoxia-targeted therapy is warranted in LSCLC.
PURPOSE: A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II study designed to confirm this result. PATIENTS AND METHODS: The concurrent phase consisted of two cycles of cisplatin, etoposide, and once-daily radiation to 61 Gy. TPZ was given at 260 mg/m(2) on days 1, 29, and at 160 mg/m(2) on days 8, 10, 12, 36, 38, and 40. Consolidation consisted of two cycles of cisplatin and etoposide. Complete responders received prophylactic cranial irradiation. Results were considered promising if the median survival time was at least 21 months and of no further interest if < or = 14 months. RESULTS: S0222 was closed early due to a report of excess toxicity for TPZ in a head and neck cancer trial elsewhere. Of planned 85 patients, 69 were accrued. In 68 assessable patients, 17 (25%) had grade 3 to 4 esophagitis and eight (12%) had grade 3 febrile neutropenia during the concurrent phase. There were three possible treatment-related deaths, two in concurrent phase (one progressive disease not otherwise specified within 30 days, one pericardial effusion) and one in consolidation phase (esophageal hemorrhage). At a median follow-up of 35 months, median progression-free survival was 11 months (95% CI, 10 to 13 months) and median overall survival was 21 months (95% CI, 17 to 33 months). CONCLUSION: S0222 showed acceptable levels of toxicity and similar promising median survival as S0004. Further study of hypoxia-targeted therapy is warranted in LSCLC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jeffrey A Bogart; James E Herndon; Alan P Lyss; Dorothy Watson; Antonius A Miller; Michael E Lee; Andrew T Turrisi; Mark R Green Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: D Rischin; L Peters; R Hicks; P Hughes; R Fisher; R Hart; M Sexton; I D'Costa; R von Roemeling Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: Nicholas C Denko; Lucrezia A Fontana; Karen M Hudson; Patrick D Sutphin; Soumya Raychaudhuri; Russ Altman; Amato J Giaccia Journal: Oncogene Date: 2003-09-01 Impact factor: 9.867
Authors: Quynh-Thu Le; Christina Kong; Phillip W Lavori; Ken O'byrne; Janine T Erler; Xin Huang; Yijun Chen; Hongbin Cao; Robert Tibshirani; Nic Denko; Amato J Giaccia; Albert C Koong Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-01 Impact factor: 7.038
Authors: M B Parliament; J D Chapman; R C Urtasun; A J McEwan; L Golberg; J R Mercer; R H Mannan; L I Wiebe Journal: Br J Cancer Date: 1992-01 Impact factor: 7.640
Authors: Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan Journal: Invest New Drugs Date: 2009-12-16 Impact factor: 3.850
Authors: Thomas E Stinchcombe; Wen Fan; Steven E Schild; Everett E Vokes; Jeff Bogart; Quynh-Thu Le; Charles R Thomas; Martin J Edelman; Leora Horn; Ritsuko Komaki; Harvey J Cohen; Apar Kishor Ganti; Herbert Pang; Xiaofei Wang Journal: Cancer Date: 2018-10-21 Impact factor: 6.860
Authors: S J Lunt; C Cawthorne; M Ali; B A Telfer; M Babur; A Smigova; P J Julyan; P M Price; I J Stratford; W D Bloomer; M V Papadopoulou; K J Williams Journal: Br J Cancer Date: 2010-06-29 Impact factor: 7.640
Authors: María L Lavaggi; Mauricio Cabrera; Cristina Pintos; Carolina Arredondo; Gisela Pachón; Jorge Rodríguez; Stella Raymondo; José Pedro Pacheco; Marta Cascante; Claudio Olea-Azar; Adela López de Ceráin; Antonio Monge; Hugo Cerecetto; Mercedes González Journal: ISRN Pharmacol Date: 2011-06-22